Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Secondary cancers, Stomach cancer
Closed
Phase 1/2
This trial is looking at trastuzumab deruxtecan for stomach cancer that has spread into the nearby tissue or to another part of the body.
It is also looking at adding another drug called pembrolizumab to trastuzumab deruxtecan. This is to find out whether this combination might work better than trastuzumab deruxtecan on its own.
The trial is open to people with stomach cancer and cancer where the food pipe meets the stomach (gastro oesophageal junction cancer) that:
has many receptors (HER2 positive)
and doctors can’t remove by surgery
Recruitment start: 15 July 2021
Recruitment end: 1 August 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Starling
AstraZeneca
Daiichi Sankyo
Last reviewed: 1 September 2022
CRUK internal database number: 17685
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
